🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

16 recruiting trials

for Rare CNS Tumor

GROWing Up With Rare GENEtic Syndromes NCT04463316n/a1 site📍 Rotterdam dr. Laura C. G. de Graaff-Herder · Tests: Retrospective file studies Rare Embryonal Tumors of the Central Nervous System: International Registry NCT05711992n/a11 sites📍 Yerevan📍 Ottawa📍 Budapest Immune Oncology Research Institute Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification NCT05259605n/a42 sites📍 Innsbruck📍 Vienna📍 Aalst European Organisation for Research and Treatment of Cancer … · Tests: Observational Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a2 sites📍 Sioux Falls📍 Sydney Sanford Health SIMPLIFication of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence NCT06878469NA2 sites📍 Milan📍 L’Aquila Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Tests: RehaCom Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases. NCT04880356n/a1 site📍 Milan Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Tests: collection of data DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. NCT05770544Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Entrectinib International Rare Brain Tumor Registry NCT05697874n/a13 sites📍 Los Angeles📍 San Francisco📍 Washington D.C. Children's National Research Institute Institutional Registry of Rare Diseases NCT06573723n/a1 site📍 Buenos Aires Hospital Italiano de Buenos Aires Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors NCT01356290Phase 222 sites📍 Chicago📍 Boston📍 Grand Rapids Medical University of Vienna · Tests: Bevacizumab, Thalidomide, Celecoxib, Fenofibric acid, Etoposide Collection of Biological Samples From Patients With Rare Neurological Diseases NCT04698421n/a1 site📍 Toulouse University Hospital, Toulouse · Tests: Blood collection on admission and longitudinally Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms NCT04541082Phase 11 site📍 Bethesda Jazz Pharmaceuticals · Tests: ONC206 Ultra-Rapid Profiling and Drug Screening for Treatment Selection in Patients With Relapsed or Recurrent Rare Brain Tumors NCT07851636NA1 site📍 Washington D.C. Adriana Fonseca · Tests: Personalized Treatment Recommendation Pharmacoscopy for Patients With Refractory Primary Brain Tumors NCT06804655Phase 23 sites📍 Basel📍 Sankt Gallen📍 Zurich University of Zurich · Tests: Pharmacoscopy 1.0 Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE) NCT07575347n/a1 site📍 Bucharest Stefan Lujinschi · Tests: Observational assessment National Registry of Rare Kidney Diseases NCT06065852n/a1 site📍 Bristol UK Kidney Association
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy